During
Tuesday’s class I attentively observed while the members of the consulting team
presented to the panel of P&G’s C-Level executives. This was followed by period
of critical questions and serious concerns posed by the executives to the consultants. Following this decorum, I took advantage of
the opportunity to voice an inquiry of my own to the consultants. Finally, I participated in a general discussion
lead by Dr. P that touched on the focal points of the case and presentation and
brought closure to the event. Coming
away from this experience, I’m now in a position to reflect and critically gauge
the degree of value that my case blog would have provided the C-Level
Executives in aiding with their decision.
I feel
there were areas of my blog I touched on but should have given greater attention
to – specifically the degree of risk involved in making a transition to web
enabled EDC. In hindsight, I would have
liked to spend more time considering the alternatives than I did. I also now wish I had evaluated the
alternatives ahead of the recommended alternative as to avoid creating the
appearance that they were merely an afterthought. However, In general I feel my first case blog
came pretty close to hitting the mark.
I did not waste the C-Level’s time giving
them “fluff” information about their company that they obviously knew. I cut
to the point by identifying the problem right out of the gate in my very first
sentence. I then conveyed the gravity of
the problem, expressing the costs in terms I felt a CEO and CFO might truly care
about — real measurable dollars. I then
immediately unveiled what I felt was the most advisable course of action to
take to remediate the problem. I outlined
what I felt were all the foreseeable benefits of this recommendation and did my
best to quantify these in terms of dollar yield they could contribute to
P&G’s top line sales and cost savings.
I did not want to oversell this recommendation or lead the C-Level’s to
believe it was a clear-cut choice free from serious costs or potential pitfalls. I devoted a large paragraph to quantifying
the associated costs of the recommendation – both those that were initial one
time investments as well as variable continual costs. I touched on some of the risks involved,
specifically relating to privacy concerns, undependable internet connections
and the leap of faith required in relying upon Phase Forward, a young company
lacking a meaningful track record. I
feel now that I should have devoted additional attention to this area of my
blog. After the presentation, it was
more apparent to me how substantial this potential move to EDC would have been
for P&G a decade ago. And the risks
of adopting this new technology were far greater than I realized. I would have spent more time voicing concerns
on what a potential information systems crash could mean for a clinical
trial. Or what the results might be if
investigator sites refused to adopt the technology. I would have put greater emphasis on the fact
this advised decision while carrying a great potential upside, is not an
obvious decision that comes without serious risks.
Overall, I feel I made the correct recommendation
and supported it with sufficient quantifiable evidence. While I covered the costs in great detail and
touched on some of the potential risks, I feel I should have addressed other possible
risks in greater scope. Without dragging
my blog out, I feel I could have explored the alternatives a bit further and
would have positioned them ahead of my evaluation of the advised course of
action. I am eager to carry these
takeaways forward into my next case blog.
Bobby
No comments:
Post a Comment